The debate over colonoscopy as a colorectal cancer screening tool has taken a new turn, with researchers arguing that the NordICC trial's results must be weighed against a much larger body of randomized evidence. In a correspondence published in The Lancet, the authors point out that four randomized controlled trials involving more than 458,000 participants have consistently shown that sigmoidoscopy reduces both the incidence of colorectal cancer and deaths from the disease.
Those four trials, the correspondence notes, found colorectal cancer incidence reductions of 18 to 23 percent and mortality reductions of 22 to 31 percent. The NordICC trial, by contrast, reported that screening reduced colorectal cancer incidence but did not produce a statistically significant reduction in mortality. The authors say that discrepancy should not be read as a verdict against endoscopy-based screening, but rather as a reason to examine how the NordICC results fit with the broader evidence base.
The NordICC trial is one of the few randomized studies to test colonoscopy directly, making its findings influential in screening policy discussions. Sigmoidoscopy, which examines only the lower part of the colon, has a longer and more consistent track record in randomized trials. The correspondence suggests that the accumulated sigmoidoscopy data provide a reliable benchmark for what endoscopic screening can achieve when uptake and follow-up are adequate.
Colorectal cancer is among the most common cancers worldwide and a leading cause of cancer death. Screening programs aim to detect precancerous polyps and early-stage tumors, when treatment is most effective. The choice between colonoscopy and sigmoidoscopy, and how often each is used, has implications for health systems weighing cost, patient acceptance, and clinical benefit.
The correspondence does not call for abandoning colonoscopy. Instead, it places the NordICC outcome in a comparative frame: the trial's incidence finding aligns with the direction seen in sigmoidoscopy studies, while its mortality result differs from the larger pooled experience. That difference, the authors indicate, deserves scrutiny rather than a simple conclusion that colonoscopy does not save lives.
For clinicians and public health officials, the message is that screening evidence is cumulative. The four sigmoidoscopy trials, with their large combined sample, offer a consistent signal that endoscopic screening can reduce deaths from colorectal cancer. The NordICC trial adds an important data point, but the correspondence argues it should be interpreted alongside, not in isolation from, that prior work.
The correspondence appears as a letter in The Lancet, a venue where researchers often debate the interpretation of major trials. Its central claim is straightforward: the NordICC trial should be considered in context with previous colorectal cancer screening studies. That context includes more than 458,000 participants across four randomized trials, a body of evidence that the authors say supports a more nuanced reading of the NordICC mortality finding.
How the debate shapes screening guidelines remains to be seen. What the correspondence makes clear is that the question is not whether endoscopic screening works, but how different endoscopic approaches and trial designs inform one another. For now, the authors urge that the NordICC results be read as part of a larger, consistent picture of colorectal cancer prevention.
13
